admin@ataxiatelangiectasia.es
Başlangıç
A-T nedir?
Arama
News
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial
Görüntüleme: 161
EryDex
Quince Therapeutics
ChromaDex wins orphan designation for rare ataxia drug
Görüntüleme: 260
EryDex
Nicotinamide Riboside
ChromaDex
FDA
Nanopore Long-Read Sequencing Facilitates Diagnosis of Atypical Ataxia-Telangiectasia
Görüntüleme: 133
Korea
late onset variant
Nanopore
Neurology Genetics
IBEC and AEFAT join forces against ataxia telangiectasia
Görüntüleme: 80
Spain
AEFAT
IBEC
Organoids to study ataxia telangiectasia
Görüntüleme: 84
Spain
IBEC
organoids
Boston Children's Hospital lab trying to develop drug to treat boy's deadly rare disease
Görüntüleme: 121
ASO
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
Görüntüleme: 65
EryDex
FDA
Quince Therapeutics
Governor of Queensland Celebrates Ataxia Telangiectasia Clinical Trial
Görüntüleme: 73
Australia
Triheptanoin
Acasti reports results from ataxia telangiectasia therapy trial
Görüntüleme: 174
GTX-102
Acasti Pharma
A New Model for Neurodegenerative Disease
Görüntüleme: 73
pig model
Arama
Başlangıç
A-T nedir?
admin@ataxiatelangiectasia.es